Company profile: BlueSphere Bio
1.1 - Company Overview
Company description
- Provider of TCXpress technology designed to unlock the potential of personalized T-cell therapy for the treatment of cancer.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BlueSphere Bio
Circassia
HQ: United Kingdom
Website
- Description: Provider of point-of-care asthma diagnostics and management solutions, including NIOX VERO and FeNO by NIOX for measuring fractional exhaled nitric oxide to assess airway inflammation, used by physicians worldwide to aid diagnosis and management, with dedicated customer service and after-sales support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Circassia company profile →
Asher Bio
HQ: United States
Website
- Description: Provider of cis-targeted cytokine immunotherapies that selectively activate CD8+ T cells for cancer and chronic viral infections. Pipeline includes AB248, a cis-targeted IL-2 in Phase 1a/1b for solid tumors; AB821, a CD8-targeted IL-21; AB359 for chronic viral infections including HBV; and cis-targeted cytokines to enhance CAR-T and other cell therapies by improving engraftment, persistence, and function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Asher Bio company profile →
Aridis Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel, differentiated biopharmaceutical therapies for infectious diseases, including AR-301, a fully human monoclonal antibody targeting S. aureus alpha-toxin to treat ventilator-associated pneumonia; AR-320, a long-acting antibody to prevent ventilator-associated pneumonia; AR-501, inhaled gallium citrate for bacterial lung infections in cystic fibrosis patients; and the MabIgX platform to discover rare, potent human monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aridis Pharmaceuticals company profile →
Thallion Pharmaceuticals
HQ: Canada
Website
- Description: Provider of biotechnology-based pharmaceutical development in infectious disease and oncology, currently emphasizing treatment for Shigatoxin-producing E. coli (STEC) bacterial infections; leading product candidate is Shigamabs®, a dual antibody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Thallion Pharmaceuticals company profile →
Sensei Bio
HQ: United States
Website
- Description: Provider of next-generation cancer immunotherapies from a clinical-stage biotechnology company, including SNS-101, a pH-sensitive monoclonal antibody that selectively targets and inhibits VISTA in the acidic tumor microenvironment to enhance T-cell activation and reduce immune suppression, and the TMAb platform for conditionally active antibodies that activate in low-pH tumors to minimize off-tumor activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sensei Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BlueSphere Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BlueSphere Bio
2.2 - Growth funds investing in similar companies to BlueSphere Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BlueSphere Bio
4.2 - Public trading comparable groups for BlueSphere Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →